BP000226-CYT-107: Recombinant Human Noggin, HEK
Source: HEK-derived.
The specific activity was determined by the dose dependent inhibition of rhBMP4 induced alkaline phosphate production by ATDC5 cells and is typically 20-100 ug/ml.
Purity > 95%, by SDS-PAGE.BP000226-CYT-475: Recombinant Human Noggin
Source: E. coli-derived.
The ED50 was determined by its ability to inhibit 5.0 ug/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 0.05-0.08 ug/ml of Noggin concentration corresponding to a Specific Activity of 12.5-20 MIU/mg.
Purity > 95%, by SDS-PAGE.BP000226-CYT-600: Recombinant Mouse Noggin
Source: E. coli-derived.
The ED50 was determined by its ability to inhibit 5.0 ug/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 1-2 ug/ml of NOGGIN corresponding to a specific activity of 0.5-1 MIU/mg.
Purity > 95%, by SDS-PAGE.